These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18063052)

  • 1. Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors.
    Bratsos I; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
    J Inorg Biochem; 2008 Apr; 102(4):606-17. PubMed ID: 18063052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity.
    Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E
    Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half-sandwich RuII-[9]aneS3 complexes with dicarboxylate ligands: synthesis, characterization and chemical behavior.
    Bratsos I; Birarda G; Jedner S; Zangrando E; Alessio E
    Dalton Trans; 2007 Sep; (36):4048-58. PubMed ID: 17828366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
    Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
    Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo.
    Arandjelovic SS; Bjelogrlic KS; Malesevic NN; Tesic LjZ; Radulovic SS
    J BUON; 2009; 14(2):271-9. PubMed ID: 19650178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity.
    Bratsos I; Simonin C; Zangrando E; Gianferrara T; Bergamo A; Alessio E
    Dalton Trans; 2011 Oct; 40(37):9533-43. PubMed ID: 21853191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The unprecedented bridging coordination mode of 1,1-cyclobutane dicarboxylate (mu-cbdc-O,O') stabilized by intramolecular hydrogen bonds in ruthenium(II) complexes.
    Bratsos I; Zangrando E; Serli B; Katsaros N; Alessio E
    Dalton Trans; 2005 Dec; (24):3881-5. PubMed ID: 16311642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.
    Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
    J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
    Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity.
    Bratsos I; Urankar D; Zangrando E; Genova-Kalou P; Košmrlj J; Alessio E; Turel I
    Dalton Trans; 2011 May; 40(19):5188-99. PubMed ID: 21465046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
    Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
    J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Light-induced anticancer activity of [RuCl2(DMSO)4] complexes.
    Brindell M; Kuliś E; Elmroth SK; Urbańska K; Stochel G
    J Med Chem; 2005 Nov; 48(23):7298-304. PubMed ID: 16279789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
    Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
    Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic insights into the chemistry of RuII complexes containing Cl and DMSO ligands.
    Mola J; Romero I; Rodríguez M; Bozoglian F; Poater A; Solà M; Parella T; Benet-Buchholz J; Fontrodona X; Llobet A
    Inorg Chem; 2007 Dec; 46(25):10707-16. PubMed ID: 18001116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
    Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
    Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
    Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG
    Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.